Drug Product Campaigning Policy

Training Module: Drug Product Campaigning Policy

1. Learning Objectives

In the high-stakes environment of sterile pharmaceutical manufacturing, strategic clarity is the primary safeguard against human error. This module is designed to bridge the gap between regulatory theory and floor-level execution by focusing on high-risk manufacturing areas. By mastering these objectives, you ensure that every action you take maintains the "state of control" required for patient safety.

Upon completion of this module, trainees will be able to:

• Define a Drug Product Campaign according to both material requirements and facility constraints.
• Distinguish between material-based campaigning and facility-based campaigning.
• Apply the principles of "full control" to the five critical operational flows (Personnel, Materials, Equipment, Product, and Waste).
• Explain the role of barrier isolator technology and Vaporized Hydrogen Peroxide (VHP) decontamination in maintaining campaign integrity.
• Summarize the specific control methods and physical evidence—such as E-Beam Tunnel operation and glove testing—required to demonstrate policy compliance.

Understanding these objectives allows us to transition from individual tasks to understanding the document hierarchy within a modern Quality Management System (QMS).

2. Where This Policy Sits in the Quality System

A Quality Policy serves as the strategic foundation of operational compliance. It is the high-level document that outlines management’s commitment and sets the "ground rules" for all subsequent activities. At DP-MFG-FACILITY, this policy ensures our campaigning practices meet Current Good Manufacturing Practices (CGMP).

The GMP document hierarchy is structured to move from general intent to specific proof:

1. Policy: This document. It defines the "What" and "Why" regarding campaign manufacturing and cross-contamination prevention.
2. SOP (Standard Operating Procedure): These provide the "How." They detail the processes referenced in the policy, such as Cleaning, Environmental Monitoring, and Area Clearance.
3. Work Instruction (WI): Highly specific, step-by-step guides for tasks such as operating the E-Beam Tunnel or performing a Decontamination Cycle.
4. Records: The absolute proof of compliance. These include Area/Line Clearance forms, Glove Testing logs, and batch records.

While the policy dictates the requirement for single-API campaigns, the supporting procedures detail the validation and documentation steps necessary to achieve it. Recognizing this structure is vital for understanding that every record you sign is a realization of management’s quality intent.

3. Why This Policy Matters

Campaigning is a high-stakes operational decision rather than a mere scheduling convenience. While processing a series of fills in sequence increases facility efficiency, it also concentrates risk. If not managed with "full control," the transition between lots could lead to catastrophic cross-contamination.

To prevent this, we maintain rigorous control over five operational flows. Compromising any of these flows places product quality and patient safety at risk:

• Personnel Flow: Preventing human-borne contaminants from entering the aseptic field.
• Materials Flow: Ensuring only validated materials for the specific API enter the campaign environment.
• Equipment Flow: Managing the movement of tools to prevent the introduction of foreign matter or previous lot residue.
• Product Flow: Protecting the drug substance from environmental exposure and lot-to-lot mix-ups.
• Waste Flow: Critically ensuring that discarded materials follow a strict path out of the sterile field to prevent them from re-entering or contaminating the active product.

Maintaining "full control" of these flows is the only way to ensure that the aseptic processing environment remains uncompromised throughout the campaign's duration.

4. Key Terms & Definitions

A shared technical vocabulary prevents the miscommunications that lead to manufacturing errors.

• Drug Product Campaign (Materials): A series of fills processed in a decontaminated barrier isolator utilizing one decontamination cycle, containing the same active pharmaceutical ingredient (API).
• Drug Product Campaign (Facility): Campaigns performed on the Syringe, Flexible, or Vial Filling Lines, all of which utilize barrier isolators.
• Barrier Isolator: Specialized technology that provides a physical seal for filling lines, surface-decontaminated using VHP.
• Decontamination Cycle (VHP): The use of Vaporized Hydrogen Peroxide to sterilize surfaces within the isolator; this cycle marks the start of a campaign.
• Restricted Access Barrier System (RABS): A control system used specifically for vial capping on the Flexible Filling Line; the policy identifies this as "non-impacting" to campaign integrity.
• API (Active Pharmaceutical Ingredient): The primary drug substance; all fills in a single campaign must share the same API.

These definitions form the non-negotiable basis for the specific principles of the policy.

5. The Policy, Principle by Principle

The following requirements govern all campaign manufacturing at DP-MFG-FACILITY:

1. Requirement for a Single Decontamination Cycle: A campaign must be processed within a barrier isolator utilizing only one decontamination cycle.
2. Same Active Pharmaceutical Ingredient (API) Requirement: Materials for all fills in a campaign must contain the same API.
3. Unique Identification: Each lot within a campaign must be assigned a unique DP-MFG-FACILITY lot number and project code.
4. Inclusion of Placebos and Varied Concentrations: A campaign may include placebos or different concentrations of the same active pharmaceutical ingredient.
5. Exclusion of Different APIs: Materials with different active pharmaceutical ingredients must never be part of the same filling campaign.